Oncternal Therapeutics Announces Presentation of Update on Phase 1/2 Clinical Trial of Cirmtuzumab in Combination with Ibrutinib at 2020 ASCO Annual Meeting
Oncternal Therapeutics, Inc. (ONCT)
Last oncternal therapeutics, inc. earnings: 8/8 04:01 pm
Check Earnings Report
Company Research
Source: Business Wire
58% complete response rate reported for patients with relapsed/refractory MCL, with a median follow-up of 8.3 months 100% progression-free survival reported for patients with CLL, with a median follow-up of 12.8 monthsCirmtuzumab continued to be well tolerated in this trial SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial, in which cirmtuzumab, an investigational anti-ROR1 monoclonal antibody, is being evaluated in combination with ibrutinib in patients with mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL). The data will be presented as part of the American Society of Clinical Oncology (ASCO) 2020 Virtual Annual Meeting, and a copy of the poster presentation will be available online at
Show less
Read more
Impact Snapshot
Event Time:
ONCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONCT alerts
High impacting Oncternal Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ONCT
News
- Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate CancerGlobeNewswire
- Oncternal Therapeutics, Inc. (NASDAQ: ONCT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswire
ONCT
Earnings
- 3/7/24 - Miss
ONCT
Sec Filings
- 3/8/24 - Form S-3
- 3/7/24 - Form 10-K
- 3/7/24 - Form 8-K
- ONCT's page on the SEC website